Micro Therapeutics Announces Dutch Court Patent Decision
27 Octubre 2003 - 6:20PM
PR Newswire (US)
Micro Therapeutics Announces Dutch Court Patent Decision IRVINE,
Calif., Oct. 27 /PRNewswire-FirstCall/ -- Micro Therapeutics, Inc.
announced today that a Dutch court has ruled that MTI's Sapphire
embolic coils infringe three patents that are held by the
University of California ("UC") and its licensee, Boston Scientific
Corporation ("BSC"). MTI is initiating actions to preserve its
ability to sell and market its embolic coils within the EU, prevent
possible injunctive actions, and file for appeal. Revenue from
MTI's Sapphire embolic coils in Europe represent between 11% and
13% of total corporate revenues. The Dutch court decision was in
conjunction with a legal action initiated by MTI in September 2002
to assert the invalidity of four patents held by the UC and BSC as
well as MTI's non-infringement of such patents. The court ruled
that one of the UC/BSC patents, which covers a dual marker band
coil delivery catheter, is invalid. About Micro Therapeutics, Inc.
Micro Therapeutics develops, manufactures and markets minimally
invasive medical devices for the diagnosis and treatment of
vascular disease. MTI's liquid embolic product, Onyx(R), and the
Sapphire family of embolic coils have been developed for use in the
treatment of cerebral vascular conditions that, if left untreated,
can lead to stroke. Onyx currently is sold throughout Europe and is
proceeding through regulatory processes in the United States. The
Sapphire coils also are currently being sold throughout Europe, and
recently received commercial clearance in the United States. The
Company also plans on making application for commercial clearances
in Japan. MTI markets more than 225 medical devices and micro
catheter products serving the neurovascular and peripheral vascular
markets. Statements contained in this press release that are not
historical information are forward-looking statements as defined
within the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those
projected or implied. Such potential risks and uncertainties
relate, but are not limited, to, in no particular order: the
enforcement of the court's ruling by the patent holders, filing an
action that would successfully permit the company to continue to
sell its embolic coils in the EU, successfully appealing the
court's ruling, and the impact of the court's ruling on the
detachable coil product line. More detailed information on these
and additional factors which could affect Micro Therapeutics,
Inc.'s operating and financial results are described in the
company's Forms 10-QSB, 10-KSB, proxy statement mailed on or about
April 28, 2003 and other reports, filed or to be filed with the
Securities and Exchange Commission. Micro Therapeutics, Inc. urges
all interested parties to read these reports to gain a better
understanding of the many business and other risks that the company
faces. Additionally, Micro Therapeutics, Inc. undertakes no
obligation to publicly release the results of any revisions to
these forward-looking statements, which may be made to reflect
events or circumstances occurring after the date hereof or to
reflect the occurrence of unanticipated events DATASOURCE: Micro
Therapeutics, Inc. CONTACT: Hal Hurwitz of Micro Therapeutics,
Inc., +1-949-837-3700, or Rob Whetstone, or Robert Jaffe, both of
PondelWilkinson MS&L, for Micro Therapeutics, Inc.,
+1-323-866-6050 Web site: http://www.microtherapeutics.com/
Copyright
Micro Therapeutics (NASDAQ:MTIX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Micro Therapeutics (NASDAQ:MTIX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Micro Therapeutics (MM) (NASDAQ): 0 recent articles
Más de Micro Therapeutics (MM) Artículos de Noticias